INTRODUCTION
Increasing numbers of AIDS patients are receiving protease inhibitors (Pis) for the treatment of their HIV infection (Generic Zerit еreating HIV infection when used in combination with other medicines). This treatment had dramatically decreased the number of opportunistic infections and mortality in AIDS. After introduction of Pis and highly active antiretroviral therapy (HAART) in the treatment of AIDS/HIV infection, many patients have developed a clinical constellation comprising three aspects:

1) lipodystrophy, with abdominal obesity, decrease of subcutaneous fat in extremities and face, and development of a buffalo hump and sometimes massive enlargement of breasts;

2) hyperlipidemia, with hypertriglyceridemia, decrease of HDL cholesterol, increase of low and very-low-density lipoprotein cholesterol, as well as apo-lipoproteins В and E2, which are highly atherogenic;

3) insulin resistance and sometimes type-2 diabetes. Recently, aseptic necrosis of the hip and osteopenia were added to this picture. Different names were given for this entity, such as pseudocushing, HIV-associated or Pi-associated lipodystrophy syndrome, fat redistribution syndrome and fat maldistribution syndrome. However, the term HAART-associated dysmetabolic syndrome will be used to define this entity in this study.

Among clinicians, HIV (Generic Viramune treating HIV infection) and AIDS were considered to have a protective effect on the development of diabetes. In our personal observation, among a cohort of 240 homosexual HIV-infected subjects from 1984-1990, when Pis were not yet available, only one patient developed diabetes mellitus type-2 (avandia 4 mg treat high blood sugar levels (sugar diabetes) called type 2 diabetes). In 1999, we observed an increasing number of HIV-infected patients with diabetes, which led us to assess the prevalence and incidence of diabetes mellitus (actos medication treat type II of diabetes) among our patients at King/Drew Medical Center.